Literature DB >> 6802182

Calcium permeability of Ehrlich ascites tumour cell plasma membrane in vivo.

A Cittadini, A M Dani, F Wolf, D Bossi, G Calviello.   

Abstract

Passive Ca2+ entry into Ehrlich ascites tumour cells has been investigated. Passive equilibrium of Ca2+ takes place in ascites tumour cells only under conditions of exhaustive energy depletion. The specific Ca2+ ionophore A23187 does not affect Ca2+ entry into ascites tumour cells under active metabolic conditions, but it increases the rate of Ca2+ equilibration in ascites tumour cells in the early stages of energy depletion. The results of the present experiments lead to the conclusion that in ascites tumour cell plasma membrane Ca2+ permeability is not a limiting step in the regulation of intracellular calcium content, while the energy-dependent Ca2+ extrusion is the main mechanism that prevents uncontrolled intracellular Ca2+ increase. The results taken together support the hypothesis that increased Ca2+ influx into the cell, caused by plasma membrane alteration, is responsible for permanently elevated mitotic activity and for deranged metabolic behavior of these neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6802182     DOI: 10.1016/0005-2736(82)90148-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Separate, Ca2+-activated K+ and Cl- transport pathways in Ehrlich ascites tumor cells.

Authors:  E K Hoffmann; I H Lambert; L O Simonsen
Journal:  J Membr Biol       Date:  1986       Impact factor: 1.843

2.  Experimental evidence for the probable involvement of calcium ion transport in 67Ga uptake by tumour cells.

Authors:  L J Anghileri; P Thouvenot; F Brunotte; J Robert
Journal:  Eur J Nucl Med       Date:  1986

3.  Plasma membrane Ca2+-ATPase mRNA expression in murine hepatocarcinoma and regenerating liver cells.

Authors:  Blanca Delgado-Coello; Juan Santiago-García; Angel Zarain-Herzberg; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.